Does the media favor FULC or HYFT?

In the previous week, Fulcrum Therapeutics had 5 more articles in the media than MindWalk. MarketBeat recorded 7 mentions for Fulcrum Therapeutics and 2 mentions for MindWalk. Fulcrum Therapeutics' average media sentiment score of 0.18 beat MindWalk's score of -0.33 indicating that Fulcrum Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Fulcrum Therapeutics 2 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral MindWalk 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is MGNX or HYFT more profitable?

MacroGenics has a net margin of -44.79% compared to MindWalk's net margin of -89.65%. MindWalk's return on equity of -92.61% beat MacroGenics' return on equity. Company Net Margins Return on Equity Return on Assets MacroGenics -44.79% -147.80% -28.40% MindWalk -89.65% -92.61% -54.15%

Does the media favor MGNX or HYFT?

In the previous week, MacroGenics and MacroGenics both had 2 articles in the media. MacroGenics' average media sentiment score of 0.67 beat MindWalk's score of -0.33 indicating that MacroGenics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MacroGenics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MindWalk 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate JMAC or HYFT?

MindWalk has a consensus price target of $5.00, suggesting a potential upside of 278.79%. Given MindWalk's stronger consensus rating and higher possible upside, analysts clearly believe MindWalk is more favorable than Maxpro Capital Acquisition. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Maxpro Capital Acquisition 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 MindWalk 2 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.40

Which has higher earnings & valuation, JMAC or HYFT?

Maxpro Capital Acquisition has higher earnings, but lower revenue than MindWalk. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Maxpro Capital Acquisition N/A N/A N/A N/A N/A MindWalk $11.24M 5.49 -$10.11M -$0.22 N/A

Do analysts prefer SIGA or HYFT?

MindWalk has a consensus price target of $5.00, suggesting a potential upside of 278.79%. Given MindWalk's stronger consensus rating and higher probable upside, analysts plainly believe MindWalk is more favorable than Siga Technologies. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Siga Technologies 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 MindWalk 2 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.40

Does the media favor SIGA or HYFT?

In the previous week, Siga Technologies and Siga Technologies both had 2 articles in the media. Siga Technologies' average media sentiment score of 0.80 beat MindWalk's score of -0.33 indicating that Siga Technologies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Siga Technologies 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MindWalk 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to HYFT or SGMT?

In the previous week, Sagimet Biosciences had 1 more articles in the media than MindWalk. MarketBeat recorded 3 mentions for Sagimet Biosciences and 2 mentions for MindWalk. Sagimet Biosciences' average media sentiment score of 0.47 beat MindWalk's score of -0.33 indicating that Sagimet Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MindWalk 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Sagimet Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

MindWalk (HYFT) Competitors

$1.32 -0.04 (-2.94%)

Closing price 08/5/2026 04:00 PM Eastern

Extended Trading

$1.33 +0.01 (+0.76%)

As of 08/5/2026 07:34 PM Eastern

Compare

HYFT vs. FULC, MGNX, JMAC, SIGA, and SGMT

Should you buy MindWalk stock or one of its competitors? MarketBeat compares MindWalk with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with MindWalk include Fulcrum Therapeutics (FULC), MacroGenics (MGNX), Maxpro Capital Acquisition (JMAC), Siga Technologies (SIGA), and Sagimet Biosciences (SGMT).

How does MindWalk compare to Fulcrum Therapeutics?

Fulcrum Therapeutics (NASDAQ:FULC) and MindWalk (NASDAQ:HYFT) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, dividends, institutional ownership, media sentiment, risk, profitability, analyst recommendations and valuation.

In the previous week, Fulcrum Therapeutics had 5 more articles in the media than MindWalk. MarketBeat recorded 7 mentions for Fulcrum Therapeutics and 2 mentions for MindWalk. Fulcrum Therapeutics' average media sentiment score of 0.18 beat MindWalk's score of -0.33 indicating that Fulcrum Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Fulcrum Therapeutics	2 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
MindWalk	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Fulcrum Therapeutics currently has a consensus price target of $8.20, indicating a potential upside of 117.51%. MindWalk has a consensus price target of $5.00, indicating a potential upside of 278.79%. Given MindWalk's stronger consensus rating and higher possible upside, analysts clearly believe MindWalk is more favorable than Fulcrum Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fulcrum Therapeutics	4 Sell rating(s)	7 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75
MindWalk	2 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.40

MindWalk has lower revenue, but higher earnings than Fulcrum Therapeutics. MindWalk is trading at a lower price-to-earnings ratio than Fulcrum Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fulcrum Therapeutics	$80M	3.60	-$74.88M	-$1.15	N/A
MindWalk	$11.24M	5.49	-$10.11M	-$0.22	N/A

Fulcrum Therapeutics has a net margin of 0.00% compared to MindWalk's net margin of -89.65%. Fulcrum Therapeutics' return on equity of -25.38% beat MindWalk's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fulcrum Therapeutics	N/A	-25.38%	-24.15%
MindWalk	-89.65%	-92.61%	-54.15%

Fulcrum Therapeutics has a beta of 3.05, suggesting that its share price is 205% more volatile than the broader market. Comparatively, MindWalk has a beta of 0.84, suggesting that its share price is 16% less volatile than the broader market.

89.8% of Fulcrum Therapeutics shares are owned by institutional investors. Comparatively, 6.7% of MindWalk shares are owned by institutional investors. 7.3% of Fulcrum Therapeutics shares are owned by company insiders. Comparatively, 6.8% of MindWalk shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Fulcrum Therapeutics beats MindWalk on 10 of the 17 factors compared between the two stocks.

How does MindWalk compare to MacroGenics?

MacroGenics (NASDAQ:MGNX) and MindWalk (NASDAQ:HYFT) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, valuation, media sentiment, earnings, analyst recommendations, profitability and risk.

In the previous week, MacroGenics and MacroGenics both had 2 articles in the media. MacroGenics' average media sentiment score of 0.67 beat MindWalk's score of -0.33 indicating that MacroGenics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MacroGenics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MindWalk	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

MindWalk has lower revenue, but higher earnings than MacroGenics. MindWalk is trading at a lower price-to-earnings ratio than MacroGenics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MacroGenics	$149.50M	1.66	-$74.62M	-$1.10	N/A
MindWalk	$11.24M	5.49	-$10.11M	-$0.22	N/A

MacroGenics has a net margin of -44.79% compared to MindWalk's net margin of -89.65%. MindWalk's return on equity of -92.61% beat MacroGenics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MacroGenics	-44.79%	-147.80%	-28.40%
MindWalk	-89.65%	-92.61%	-54.15%

MacroGenics presently has a consensus price target of $5.50, indicating a potential upside of 41.03%. MindWalk has a consensus price target of $5.00, indicating a potential upside of 278.79%. Given MindWalk's stronger consensus rating and higher possible upside, analysts clearly believe MindWalk is more favorable than MacroGenics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MacroGenics	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29
MindWalk	2 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.40

MacroGenics has a beta of 1.2, meaning that its stock price is 20% more volatile than the broader market. Comparatively, MindWalk has a beta of 0.84, meaning that its stock price is 16% less volatile than the broader market.

96.9% of MacroGenics shares are held by institutional investors. Comparatively, 6.7% of MindWalk shares are held by institutional investors. 13.6% of MacroGenics shares are held by insiders. Comparatively, 6.8% of MindWalk shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

MacroGenics beats MindWalk on 9 of the 16 factors compared between the two stocks.

How does MindWalk compare to Maxpro Capital Acquisition?

Maxpro Capital Acquisition (NASDAQ:JMAC) and MindWalk (NASDAQ:HYFT) are related small-cap companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, dividends, media sentiment, risk, valuation, profitability, analyst recommendations and institutional ownership.

Maxpro Capital Acquisition has a net margin of 0.00% compared to MindWalk's net margin of -89.65%. Maxpro Capital Acquisition's return on equity of 0.00% beat MindWalk's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Maxpro Capital Acquisition	N/A	N/A	N/A
MindWalk	-89.65%	-92.61%	-54.15%

MindWalk has a consensus price target of $5.00, suggesting a potential upside of 278.79%. Given MindWalk's stronger consensus rating and higher possible upside, analysts clearly believe MindWalk is more favorable than Maxpro Capital Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Maxpro Capital Acquisition	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
MindWalk	2 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.40

Maxpro Capital Acquisition has a beta of 0.01, indicating that its share price is 99% less volatile than the broader market. Comparatively, MindWalk has a beta of 0.84, indicating that its share price is 16% less volatile than the broader market.

In the previous week, MindWalk had 2 more articles in the media than Maxpro Capital Acquisition. MarketBeat recorded 2 mentions for MindWalk and 0 mentions for Maxpro Capital Acquisition. Maxpro Capital Acquisition's average media sentiment score of 0.00 beat MindWalk's score of -0.33 indicating that Maxpro Capital Acquisition is being referred to more favorably in the media.

Company	Overall Sentiment
Maxpro Capital Acquisition	Neutral
MindWalk	Neutral

73.2% of Maxpro Capital Acquisition shares are owned by institutional investors. Comparatively, 6.7% of MindWalk shares are owned by institutional investors. 19.3% of Maxpro Capital Acquisition shares are owned by insiders. Comparatively, 6.8% of MindWalk shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Maxpro Capital Acquisition has higher earnings, but lower revenue than MindWalk.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Maxpro Capital Acquisition	N/A	N/A	N/A	N/A	N/A
MindWalk	$11.24M	5.49	-$10.11M	-$0.22	N/A

Summary

MindWalk beats Maxpro Capital Acquisition on 7 of the 13 factors compared between the two stocks.

How does MindWalk compare to Siga Technologies?

Siga Technologies (NASDAQ:SIGA) and MindWalk (NASDAQ:HYFT) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, earnings, dividends, analyst recommendations, valuation and profitability.

Siga Technologies has a beta of 0.97, suggesting that its share price is 3% less volatile than the broader market. Comparatively, MindWalk has a beta of 0.84, suggesting that its share price is 16% less volatile than the broader market.

Siga Technologies has a net margin of 21.58% compared to MindWalk's net margin of -89.65%. Siga Technologies' return on equity of 10.60% beat MindWalk's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Siga Technologies	21.58%	10.60%	8.94%
MindWalk	-89.65%	-92.61%	-54.15%

55.4% of Siga Technologies shares are held by institutional investors. Comparatively, 6.7% of MindWalk shares are held by institutional investors. 2.7% of Siga Technologies shares are held by insiders. Comparatively, 6.8% of MindWalk shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Siga Technologies and Siga Technologies both had 2 articles in the media. Siga Technologies' average media sentiment score of 0.80 beat MindWalk's score of -0.33 indicating that Siga Technologies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Siga Technologies	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MindWalk	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Siga Technologies has higher revenue and earnings than MindWalk. MindWalk is trading at a lower price-to-earnings ratio than Siga Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Siga Technologies	$94.57M	2.39	$23.28M	$0.27	11.67
MindWalk	$11.24M	5.49	-$10.11M	-$0.22	N/A

MindWalk has a consensus price target of $5.00, suggesting a potential upside of 278.79%. Given MindWalk's stronger consensus rating and higher probable upside, analysts plainly believe MindWalk is more favorable than Siga Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Siga Technologies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
MindWalk	2 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.40

Summary

Siga Technologies beats MindWalk on 10 of the 16 factors compared between the two stocks.

How does MindWalk compare to Sagimet Biosciences?

MindWalk (NASDAQ:HYFT) and Sagimet Biosciences (NASDAQ:SGMT) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, earnings, profitability, media sentiment, institutional ownership, risk and dividends.

MindWalk has a beta of 0.84, suggesting that its share price is 16% less volatile than the broader market. Comparatively, Sagimet Biosciences has a beta of 3.37, suggesting that its share price is 237% more volatile than the broader market.

Sagimet Biosciences has a net margin of 0.00% compared to MindWalk's net margin of -89.65%. Sagimet Biosciences' return on equity of -37.57% beat MindWalk's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MindWalk	-89.65%	-92.61%	-54.15%
Sagimet Biosciences	N/A	-37.57%	-35.52%

In the previous week, Sagimet Biosciences had 1 more articles in the media than MindWalk. MarketBeat recorded 3 mentions for Sagimet Biosciences and 2 mentions for MindWalk. Sagimet Biosciences' average media sentiment score of 0.47 beat MindWalk's score of -0.33 indicating that Sagimet Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MindWalk	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Sagimet Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

6.7% of MindWalk shares are held by institutional investors. Comparatively, 87.9% of Sagimet Biosciences shares are held by institutional investors. 6.8% of MindWalk shares are held by insiders. Comparatively, 11.5% of Sagimet Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

MindWalk has higher revenue and earnings than Sagimet Biosciences. Sagimet Biosciences is trading at a lower price-to-earnings ratio than MindWalk, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MindWalk	$11.24M	5.49	-$10.11M	-$0.22	N/A
Sagimet Biosciences	N/A	N/A	-$51.04M	-$1.34	N/A

MindWalk currently has a consensus target price of $5.00, indicating a potential upside of 278.79%. Sagimet Biosciences has a consensus target price of $25.57, indicating a potential upside of 195.97%. Given MindWalk's higher probable upside, equities analysts plainly believe MindWalk is more favorable than Sagimet Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MindWalk	2 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.40
Sagimet Biosciences	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64

Summary

Sagimet Biosciences beats MindWalk on 10 of the 16 factors compared between the two stocks.

Get MindWalk News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HYFT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

HYFT vs. The Competition

Export

Metric	MindWalk	Life Sciences Tools & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$63.53M	$9.17B	$6.87B	$12.98B
Dividend Yield	N/A	1.47%	2.60%	9.79%
P/E Ratio	-6.00	60.69	280.34	25.27
Price / Sales	5.49	106.54	603.95	94.35
Price / Cash	N/A	25.96	71.79	50.79
Price / Book	7.33	38.22	12.97	6.09
Net Income	-$10.11M	$57.47B	$3.49B	$347.95M
7 Day Performance	-3.79%	1.53%	2.42%	3.11%
1 Month Performance	-19.51%	-2.09%	-2.87%	-2.99%
1 Year Performance	N/A	20.33%	75.29%	20.51%

MindWalk Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
HYFT MindWalk	2.165 of 5 stars	$1.32 -2.9%	$5.00 +278.8%	N/A	$63.53M	$11.24M	N/A	80
FULC Fulcrum Therapeutics	3.5265 of 5 stars	$3.53 -5.2%	$8.20 +132.6%	-45.2%	$235.55M	N/A	N/A	100	Earnings Report
MGNX MacroGenics	2.5003 of 5 stars	$3.67 -2.9%	$5.50 +49.8%	+130.8%	$233.58M	$149.50M	N/A	430	Upcoming Earnings
JMAC Maxpro Capital Acquisition	N/A	$17.35 -0.7%	N/A	+199.4%	$232.98M	N/A	N/A	2,021
SIGA Siga Technologies	0.8222 of 5 stars	$3.20 -1.7%	N/A	-52.3%	$229.16M	$93.78M	11.83	40	Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:HYFT) was last updated on 8/6/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

MindWalk (HYFT) Competitors

HYFT vs. FULC, MGNX, JMAC, SIGA, and SGMT

How does MindWalk compare to Fulcrum Therapeutics?

Summary

How does MindWalk compare to MacroGenics?

Summary

How does MindWalk compare to Maxpro Capital Acquisition?

Summary

How does MindWalk compare to Siga Technologies?

Summary

How does MindWalk compare to Sagimet Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HYFT vs. The Competition

MindWalk Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

MindWalk (HYFT) Competitors

HYFT vs. FULC, MGNX, JMAC, SIGA, and SGMT

How does MindWalk compare to Fulcrum Therapeutics?

Does the media favor FULC or HYFT?

Do analysts prefer FULC or HYFT?

Which has higher valuation & earnings, FULC or HYFT?

Is FULC or HYFT more profitable?

Which has more risk and volatility, FULC or HYFT?

Do insiders & institutionals have more ownership in FULC or HYFT?

Summary

How does MindWalk compare to MacroGenics?

Does the media favor MGNX or HYFT?

Which has better earnings and valuation, MGNX or HYFT?

Is MGNX or HYFT more profitable?

Do analysts recommend MGNX or HYFT?

Which has more risk & volatility, MGNX or HYFT?

Do institutionals and insiders believe in MGNX or HYFT?

Summary

How does MindWalk compare to Maxpro Capital Acquisition?

Is JMAC or HYFT more profitable?

Do analysts rate JMAC or HYFT?

Which has more risk & volatility, JMAC or HYFT?

Does the media favor JMAC or HYFT?

Do insiders & institutionals hold more shares of JMAC or HYFT?

Which has higher earnings & valuation, JMAC or HYFT?

Summary

How does MindWalk compare to Siga Technologies?

Which has more volatility & risk, SIGA or HYFT?

Is SIGA or HYFT more profitable?

Do institutionals & insiders have more ownership in SIGA or HYFT?

Does the media favor SIGA or HYFT?

Which has preferable earnings & valuation, SIGA or HYFT?

Do analysts prefer SIGA or HYFT?

Summary

How does MindWalk compare to Sagimet Biosciences?

Which has more risk and volatility, HYFT or SGMT?

Is HYFT or SGMT more profitable?

Does the media refer more to HYFT or SGMT?

Do institutionals & insiders believe in HYFT or SGMT?

Which has higher valuation and earnings, HYFT or SGMT?

Do analysts prefer HYFT or SGMT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HYFT vs. The Competition

MindWalk Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools